GKOS Stock — Glaukos Corp.

Glaukos Corp. (GKOS)

Updated October 16, 2026.

GKOS is a Stock. Total return is 428.0% over the past 11.3 years, 90.7 points ahead of SPY at 337.3%.

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that develops therapies for glaucoma, corneal disorders, and retinal diseases. Its product portfolio includes micro-bypass stents (iStent, iStent inject W, iStent infinite), an intraocular pressure-reduction therapy (iDose TR), and platforms in development for corneal and retinal conditions, sold through direct sales and distributors to surgery centers, hospitals, and physician practices. The company does not currently have an established distribution program.

GKOS performance versus SPY

Price and return data through 2026-10-16.

Total return is 428.0% over the past 11.3 years, 90.7 points ahead of SPY at 337.3%. Over the past year its total return — price change plus distributions reinvested — is 93.2%. Its deepest 1-year drawdown was 28.4%.

GKOS key facts

Asset type

Stock

Asset class

Equity

Inception date

06/25/2015

Distribution frequency

None

Last close

$164.84 (as of 2026-10-16)

Market cap

$9,722,912,175

Average volume

1032191.0

Beta

0.695

Payout ratio

0.0%

Forward P/E

1666.6667

EPS

$-3.31

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GKOS risks and drawbacks

The deepest 1-year drawdown on record here is 28.4%.

Who may consider GKOS — and who may not

It is a weaker fit for investors who need monthly cash flow (GKOS does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on GKOS

• ETFs holding GKOS
• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions